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OBJECTIVES We examined the prevalence, genotype-phenotype correlation, and natural history of lamin
A/C gene (LMNA) mutations in subjects with dilated cardiomyopathy (DCM).
BACKGROUND Mutations in LMNA have been found in patients with DCM with familial conduction defects
and muscular dystrophy, but the clinical spectrum, prognosis, and clinical relevance of
laminopathies in DCM are unknown.
METHODS A cohort of 49 nuclear families, 40 with familial DCM and 9 with sporadic DCM (269
subjects, 105 affected), was screened for mutations in LMNA using denaturing high-
performance liquid chromatography and sequence analysis. Bivariate analysis of clinical
predictors of LMNA mutation carrier status and Kaplan-Meier survival analysis were
performed.
RESULTS Mutations in LMNA were detected in four families (8%), three with familial (R89L, 959delT,
R377H) and one with sporadic DCM (S573L). There was significant phenotypic variability,
but the presence of skeletal muscle involvement (p  0.001), supraventricular arrhythmia
(p  0.003), conduction defects (p  0.01), and “mildly” DCM (p  0.006) were predictors
of LMNA mutations. The LMNA mutation carriers had a significantly poorer cumulative
survival compared with non-carrier DCM patients: event-free survival at the age of 45 years
was 31% versus 75% in non-carriers.
CONCLUSIONS Mutations in LMNA cause a severe and progressive DCM in a relevant proportion of
patients. Mutation screening should be considered in patients with DCM, in particular when
clinical predictors of LMNA mutation are present, regardless of family history. (J Am Coll
Cardiol 2003;41:771–80) © 2003 by the American College of Cardiology Foundation
Dilated cardiomyopathy (DCM) is a severe disease of heart
muscle characterized by progressive ventricular dilation and
impaired systolic function. Population surveys estimated a
prevalence of 1 DCM case in 2,500 individuals (1). In
recent years the contribution of genetic mutations to the
etiology of DCM has been appreciated. Familial dilated
cardiomyopathy (FDC) is now estimated to account for as
many as 50% of all cases of “idiopathic” DCM (2,3).
Mutations in 10 cytoskeletal/sarcomeric protein-encoding
genes have been identified in FDC, including dystrophin
(4,5), desmin (6), lamin A/C (7–9), cardiac actin (10),
tafazzin (11), cardiac beta-myosin heavy chain and cardiac
troponin T (12), alpha-tropomyosin (13), delta-sarcoglycan
(14), and titin (15).
The lamin A/C gene (LMNA) maps on the long arm of
chromosome 1 (1q21.2-q21.3) and encodes two main iso-
forms by alternative splicing (16), lamin A and C. Lamin
proteins are type V intermediate filaments, major compo-
nents of the nuclear lamina (a filamentous structure that
supports the inner nuclear membrane), and are classified as
A-type or B-type (17,18). A-type lamins (lamin A and C)
are expressed exclusively in differentiated non-proliferating
cells (18,19). Mutations in LMNA cause DCM, frequently
complicated by conduction system defects and variable
skeletal muscle involvement (7,9,20–22). The LMNA mu-
tations have also been reported in autosomal dominant (23)
and recessive (24) Emery-Dreifuss muscular dystrophy
(EDMD), autosomal dominant limb-girdle muscular dys-
trophy (LGMD) (8), sensory and motor axonal neuropathy
Charcot-Marie-Tooth type 2 (25), and familial partial
lipodystrophy, characterized by the development of abnor-
mal patterns of adipose tissue distribution (26,27).
The prevalence of LMNA mutations in patients with
DCM, the genotype-phenotype correlations, and the im-
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pact on survival are still unknown. Over the past two
decades, we have studied families with both FDC and
sporadic DCM (28,29). Here we report the results of our
comprehensive genetic screening of LMNA in 49 unrelated
families comprised of 40 familial and 9 sporadic cases of
DCM.
METHODS
Patient population. The 49 families of patients with
DCM (269 subjects, 105 affected) were evaluated by the
investigators in Europe and the U.S. Subjects (probands and
family members) with DCM were recruited from general
cardiology clinics at the University of Colorado Health
Sciences Center and Children’s Hospital (Denver, Colo-
rado) and the University of Trieste (Trieste, Italy) from
1991 to 2001 (28,29). Subjects were identified solely on the
basis of having DCM and were not prescreened or prese-
lected for any neuromuscular, cardiac conduction, or any
other non-cardiac phenotype. Detailed clinical information
was obtained from each subject, including family history;
age of presentation; initial symptoms of heart failure;
New York Heart Association classification; physical exam-
ination; serum creatine kinase (MM isoform); electrocar-
diograms, echocardiograms, and, when appropriate, Holter
monitoring; treadmill testing; invasive examination (right
and left heart catheterization, ventriculography, coronary
angiogram, and endomyocardial biopsy); and neuromuscu-
lar investigations (electromyography and skeletal muscle
biopsy).
The diagnostic criteria for FDC followed the Guidelines
for the Study of Familial Dilated Cardiomyopathies (30). In
brief, individuals were classified as affected on the basis of
major and minor criteria. The major criteria were: 1) left
ventricular ejection fraction45% or frameshift25%, and
2) left ventricular end-diastolic dimension 117% of the
predicted value corrected for age and body surface area
(31). Individuals were classified as healthy when found to
be normal or affected by known diseases and unknown
when isolated minor cardiac or skeletal muscle abnormal-
ities were observed, as described in detail previously (30).
The final study population included 40 unrelated families
with FDC, and 9 with non-familial sporadic DCM
(Table 1). Families with X-linked DCM due to dystro-
phin gene mutations (32,33) were excluded from the
mutation analysis. Written informed consent was ob-
tained from all subjects.
Genetic analysis. Genomic deoxyribonucelic acid (DNA)
was extracted from blood leukocytes according to standard
techniques. Polymerase chain reaction (PCR) primers (Life
Technologies, Carlsbad, California) were designed to am-
plify all protein coding exons of LMNA, and denaturing
high-performance liquid chromatography (DHPLC) anal-
ysis was carried out on a WAVE DNA fragment analysis
system (Transgenomic, San Jose, California). Elution pro-
files that differed from wild-type patterns were selected for
sequence analysis, purified using QIAquick PCR Purifica-
tion Kits (Qiagen, Valencia, California), and then se-
quenced bidirectionally using an ABI 377 DNA sequencer
(Applied Biosystem, Foster City, California). Putative
disease-causing mutations were evaluated for segregation
with DCM phenotype within a family and were analyzed
for change in predicted amino acid sequence, predicted
protein secondary and tertiary structure, and for alterations
in ribonucelic acid (RNA) splicing. In the cases of predicted
changes in amino acid sequence, the altered residues were
analyzed for conservation across different species. A genetic
change was considered to be a putative disease-causing
mutation when it altered the predicted amino acid sequence,
cosegregated with the disease within the family, was absent
in over 150 normal, ethnically matched controls (300
chromosomes, p 0.05) (34) (data not shown), was altering
Abbreviations and Acronyms
DCM  dilated cardiomyopathy
DHPLC  denaturing high-performance liquid
chromatography
DNA  deoxyribonucelic acid
EDMD  Emery-Dreifuss muscular dystrophy
FDC  familial dilated cardiomyopathy
LGMD  limb-girdle muscular dystrophy
LMNA  lamin A/C gene
MDDC  dilated cardiomyopathy with muscle disease
PCR  polymerase chain reaction
RNA  ribonucelic acid
SNP  single-nucleotide polymorphism
Table 1. Phenotypic Characterization (29) and Molecular Epidemiology of the Study Population
Phenotype
Number of
Families
Subjects
Examined
Affected
Subjects
Families With
LMNA Mutation
Familial DCM, total 40 236 95 3
Autosomal dominant 25 163 62 1
Autosomal recessive 4 15 7 —
With conduction defect 3 18 8 —
With muscle disease 4 27 11 2
X-linked 2 5 3 —
Unclassifiable 2 8 4 —
Sporadic DCM 9 33 10 1
Total 49 269 105 4
DCM  dilated cardiomyopathy; LMNA  lamin A/C gene.
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Figure 1. The denaturing high performance liquid chromatography elution profiles for lamin A/C gene (LMNA) mutations detected in three families with dilated cardiomyopathy. (Top) Pedigree of the
families: individuals are indicated by generation and pedigree number. Affected status is indicated by filled symbols, unaffected by clear symbols. The () and () symbols indicate the presence of the mutant
allele and the wild type, respectively. (Middle) Elution profiles for the wild-type and patients carrying the LMNA mutations (G266T: III-2; 959delT: II-1; G1130A: II-2; C1718T: II-2). (Bottom) The direct
sequencing results illustrate the corresponding nucleotide substitutions (reverse sequence shown for G1130A mutation).
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a highly conserved residue throughout evolution, and was
predicted to alter any combination of protein structure,
charge, or function.
Statistical analysis. Comparison of predictor variables and
carrier status was done by Fisher exact test for binary predictors
and by the Wilcoxon rank-sum test for continuous predictors.
Table 2. Phenotype and Genotype of 12 Patients with DCM Heterozygous for LMNA Mutations
Family Mutation Codon Exon ID Age Gender NYHA CK-MM Arrhythmia
TSFDC13 G266T R89L 1 II-2 39 M 4 N Atrial fibrillation
II-2 23† F 3 N Sinus rhythm
II-1 22 M 4 Upper N Ventricular tachycardia
Atrial ectopy
MDDC1§ 959delT 320 6 II-1 22 M 2 N-3X Ventricular and supraventricular
tachycardia
II-5 30 M 3 N Atrial fibrillation
Ventricular tachycardia
III-1 4 F 1 N Atrial ectopy
III-3 16 M 1 3X Supraventricular tachycardia
Ventricular ectopy
III-4 18 F 1 4X Supraventricular tachycardia
DNFDC33 G1130T R377H 6 I-2 40 F 2
II-2 31 F 3 Upper N Atrial fibrillation
Ventricular tachycardia
Ventricular fibrillation
SDCM8 C1718T S573L 11 II-2 50 F 3 N Ventricular tachycardia
Ventricular ectopy
II-3 60 F 1 N Sinus rhythm
*At autopsy. †Peri-partum. ‡At heart transplant. §Reported by Brodsky et al. (9).
CK-MM  creatine kinase, MM isoform; DCM  dilated cardiomyopathy; EDMD  Emery-Dreifuss muscular dystrophy; LVEF  ejection fraction (%); FS  fractional
shortening; ID  pedigree identification number; LGMD  limb-girdle muscular dystrophy; LMNA  lamin A/C gene; LVEDD  left ventricular end-diastolic dimension
(31); N  normal; NYHA  New York Heart Association (class).
Figure 2. Structure of lamin A/C gene (LMNA) and of the lamin A/C protein. LMNA encodes lamin A (664 amino acids) and lamin C (572 amino acids)
by alternative splicing in exon 10. The region common to both lamins includes the globular head, the -helical domain (coils 1a, 1b, and 2, separated by
linkers depicted as diagonal stripes), and part of the tail (566 amino acids). The mutations identified in patients with DCM, the corresponding nucleotide,
and their position on the protein are indicated (star  splice site mutation).
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Event-free survival analyses used 2  2 contingency
tables for occurrence of event and the Cox proportional
hazards model for time from birth to event, comparing by
carrier status. Three survival events were used: major cardiac
event, transplant, and cardiovascular death. A major cardiac
event was defined as: 1) hospitalization for worsening heart
failure, 2) hospitalization for major arrhythmia (hypokinetic
or hyperkinetic), or 3) a thromboembolic event. As these
survival events constituted competing risks, analyses used
only the following outcomes: composite of major cardiac
event, transplant, and death; composite of transplant and
death; and death alone. For composite outcomes, survival
time was time to first occurring event.
The primary survival method used was the Cox model
utilizing the SAS procedure PHREG, with the family-
specific variable “carrier status” as the predictor of interest.
The 105 affected subjects are not independent, but nested
in 49 families. As several families had data for only a
single affected individual, it was not possible to control
for the nesting in the final statistical analysis. The
primary analysis compared LMNA mutation “carrier”
versus “non-carrier” status for the entire group of affected
individuals; analyses restricted to the probands only
provided secondary results.
Statistical software used was SAS Version 6.12 (SAS
Institute, Cary, North Carolina). Unless otherwise stated,
data are given as means  SEM. Two-sided statistical
significance was taken as p 0.05. Expected left ventricular
end-diastolic dimension was calculated by correcting for
body surface area and age (31). Survival curves were esti-
mated by the Kaplan-Meier method.
RESULTS
Genotype analysis. Mutation screening found putative
mutations in 4 of 49 families (8%) (Fig. 1, Table 2). In exon
1, a G266T missense mutation was found in one Italian
family with autosomal dominant FDC. The change predicts
an arginine (basic) to leucine (hydrophobic) substitution
(R89L) in a conserved residue located (16) in the coil 1b of
the alpha-helical rod domain (Fig. 2). In exon 6, a single
base deletion (959delT) was identified in another Italian
family with autosomal dominant FDC with muscle disease
(MDDC). As previously reported (9), this mutation pre-
dicts a frameshift that is expected to completely disrupt the
lamin A and C sequences starting from codon 320. Also in
exon 6, a LMNA mutation was found in an American family
of British descent with MDDC. This G1130A missense
mutation predicts an arginine to histidine substitution
(R377H) at a highly conserved residue. All mutations
involved conserved residues (Fig. 3), cosegregated with the
disease within the families, and were absent in 300 control
chromosomes.
A missense mutation (C1718T) was found in one of the
nine sporadic cases of DCM, in a family of Italian origin. A
serine (hydrophilic) to a leucine (hydrophobic) (S573L)
substitution is predicted to affect the carboxyl tail of the
lamin A isoform (Fig. 2). This residue is also highly
conserved (Fig. 3), and the mutation was absent in 300
control chromosomes and in a total of 450 chromosomes.
The mutation was absent in the proband’s two unaffected
offspring, whereas it was found in one clinically unaffected
sister.
Table 2 Continued
Conduction LVEDD FS LVEF Muscular Disease Outcome Age
N Dilation* Muscular atrophy* Congestive heart failure, death 41
N Dilation‡ no Transplant 25
1° Atrioventricular block 6.3 10 27 no Congestive heart failure 23
Sudden death
2°–3° Atrioventricular block 5.9 12 30 Mild LGMD Transplant 33
Left bundle-branch block Restrictive pattern
2°–3° Atrioventricular block 6 24 48 no Congestive heart failure 32
Sudden death
Left bundle-branch block
N 2.8 36 Minimal weakness Left ventricular dysfunction 6
N 4.8 33 49 Mild LGMD Transplant 20
Left anterior hemiblock 4.5 37 63 Mild EDMD Stable 21
Mild LGMD Congestive heart failure, death 62
Cardiac defibrillator 4.18 30 Mild EDMD Cardiac arrest 56
Pacemaker Restrictive pattern Congestive heart failure, death
N 7 17 20 no Stable 60
N N N N no Stable
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A total of five exonic (silent) mutations, six intronic
single-nucleotide polymorphisms (SNPs) substitutions, and
one SNP in the 3 untranslated region were each found in
a proportion of the 76 study subjects and are reported in the
National Center for Biotechnology Information Single Nu-
cleotide Polymorphism database. None of these nucleotide
changes predicted a change in amino acid sequence, coseg-
regated with the disease within the family pedigrees, or
predicted altered RNA splicing.
Phenotype analysis. The mutations were found in families
with autosomal dominant isolated FDC, autosomal domi-
nant FDC with variable muscle disease (MDDC), and in
sporadic DCM (Table 1). The expressed phenotype in the
12 LMNA mutation carriers was highly variable (Table 2).
The age of onset of DCM ranged from 4 to 59 years. Serum
creatine kinase was elevated or “high-normal” in five cases.
Seven patients had clinical skeletal muscle involvement,
ranging from modest proximal weakness in a 4-year-old
subject, to mild signs compatible with an EDMD diagnosis
(Fig. 4), to disabling LGMD in a 56-year-old subject.
Conduction defects were present in 5 of 12 subjects.
Genotype-phenotype correlation. Clinical variables and
outcome events were compared between LMNA mutation
carriers (n  12) and DCM patients without LMNA
mutations (n  93). In carriers, there was a trend toward a
younger age of disease onset (27  5 years vs. 37  2 years,
p  0.08) and a greater prevalence of females (58% vs. 34%,
p  0.12). Bivariate clinical predictors of carrier status were
the presence of supraventricular arrhythmia (73% vs. 26%,
p  0.003), conduction disease (including atrioventricular
blocks and need of a pacemaker; 50% vs. 11%, p  0.01),
and skeletal muscle involvement (including clinical or his-
tological signs of muscular dystrophy, or increased serum
creatine kinase; 67% vs. 7%, p  0.002), where the
respective proportions are for carriers and non-carriers.
Figure 3. Amino acid sequences alignment for lamin proteins from various species. The conservation of the residues corresponding to the R89L, R377H,
and S573L mutations is shown. The corresponding GenBank accession numbers are listed in the column at far right.
Figure 4. Skeletal muscle biopsy in dilated cardiomyopathy due to lamin-
opathy. (A) Family MDDC1, Patient III-4 (hematoxylin-eosin, 40), and
(B) family DNFDC33, Patient II-2 (trichrome, 40). Vastus lateralis
muscle biopsies showing variability in fiber size, some angulated fibers, and
several internal nuclei.
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Indexes of myocardial function, including ejection fraction
and hemodynamic variables, were not different in the two
groups. However, carriers had a lesser degree of dilation of
the left ventricle than expected, also after correction for
body surface area and age (p  0.006) (31) (Table 3).
Survival analysis. Carriers were characterized by a signif-
icantly worse prognosis compared with non-carriers. By
analysis of contingency tables, the relative risk was 2.6 (5/12
vs. 15/93, p  0.05) for cardiovascular death, 3.4 (8/12 vs.
18/93, p  0.001) for cardiovascular death or transplant,
and 2.2 (9/12 vs. 32/93, p  0.01) for cardiovascular death,
transplant, or major event. Kaplan-Meier survival curves for
time to each of three outcomes are shown in Figure 5. By
age 45, event-free survival in carriers compared with non-
carriers was 62% versus 90%, 45% versus 89%, and 31%
versus 75% (panels A, B, and C, respectively). Using the
Cox proportional hazards models, for the three outcomes
considered, the hazard ratios for experiencing an event for
LMNA mutation carriers compared with non-carriers were
4.3 (p  0.007), 5.6 (p  0.0001), and 3.7 (p  0.0008),
respectively. These results were in agreement with results
from a secondary analysis restricted only to probands: 5.9
(p  0.04), 6.1 (p  0.01), and 4.2 (p  0.01), respectively.
DISCUSSION
Prevalence of LMNA mutations in DCM. We have
extensively characterized the LMNA gene in a series of
DCM families using a sensitive and efficient method of
screening based on DHPLC and sequence analysis. A
clinically significant frequency of disease-causing mutations
was found in the overall population (8% of the families),
both in the familial (7%) and in the sporadic (11%) forms.
Mutations of LMNA were associated with a wide range of
phenotypes, and the LMNA mutation carriers had a severe
prognosis and had higher event-rates compared with the
non-carriers. Our findings suggest that LMNA mutations
Table 3. Analysis of Clinical Variables as Predictors of LMNA
Mutations in Patients With DCM
Variable
Non-Carriers
(n  93)
Carriers
(n  12) p Value
Male gender (%) 66 42 0.12
Age of onset (yrs) 38 (2)* 28 (5) 0.08
NYHA functional class 1.76 (0.10) 2.23 (0.37) 0.20
Skeletal muscle involvement (%) 5 58 0.00001
Supraventricular arrhythmia (%) 26 73 0.003
Conduction defects (%) 10 62 0.01
LVEF (EF unit) 32 (1.5) 38 (6) 0.23
LVEDD (cm) 6.41 (0.12) 5.02 (0.49) 0.008
LVEDD, % of expected† 140 (2) 112 (9) 0.006
CI (L/m/m2) 4.3 (0.4) 2.9 (0.3) 0.07
PCWP (mm Hg) 12 (1) 13 (1) 0.46
CK-MM (U/ml) 85 (11) 288 (88) 0.003
*Standard error in parentheses. †Expected based on predicted value for age and body
surface area.
CI  cardiac index; LVEF  left ventricular ejection fraction; PCWP 
pulmonary capillary wedge pressure. Other abbreviations as in Table 2.
Figure 5. Kaplan-Meier cumulative survival curves for (A) cardio-
vascular death, (B) cardiovascular death or transplant, and (C) cardio-
vascular death, transplant, or major cardiac events in 105 patients with
dilated cardiomyopathy, carriers of lamin A/C gene mutations (dashed
lines), and non-carriers (solid lines). P values are derived by Cox
regression.
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are clinically relevant in a substantial subset of patients
diagnosed with DCM.
Spectrum of LMNA mutations in DCM. To date,
LMNA mutations causing DCM have been reported in all
but two exons, 2 and 12 (Table 4) (7,8,35) and occur in
protein coding regions (Fig. 2 and Table 4), with the
exception of a splice donor site mutation in intron 9 (8).
The DCM-causing mutations are distributed throughout
the rod and tail domains of the protein, whereas in familial
partial lipodystrophy, mutations have been reported exclu-
sively in exon 8 (36).
All mutations observed in this study altered highly
conserved regions of the LMNA gene. The R89L missense
mutation may disrupt the heptad pattern of coil 1b which is
characterized by hydrophobic residues in the first and fourth
positions, charged residues in the fifth and seventh posi-
tions, and polar residues elsewhere (18,37). An interruption
of this pattern predicts a disruption of the alpha-helix of the
rod domain, which could affect the dimerization and assem-
bly of lamins A and C. The single base deletion (959delT)
(9) is predicted to disrupt the reading frame from exon 6,
thereby generating a truncated mutant protein with a novel
carboxy-terminus that would lack the C-terminal globular
domain, the lamin A processing domain, and the nuclear
localization signal (16). The missense mutation R377H
occurs in a 30 amino acid segment at the C-terminal end of
Table 4. Summary of the Reported LMNA Mutations Leading to Cardiac Disease (DCM and/or Arrhythmia/Conduction Disease)
Exon
Nucleotide
Change
Amino Acid
Change Domain Cardiomyopathy
Arrhythmia/
Conduction
Anomaly
Muscle
Disease
Familial (F)/
Sporadic (S)
Reference
Number
1 C16T Q6X Head Y Y Y F (23)
1 G149C R50P Coil 1a N Y Y S (35)
1 C178G R60G Coil 1a Y Y N F (7)
1 T188G I63S Coil 1a Y Y Y S (35)
1 T254G L85R Coil 1b Y Y N F (7)
1 G266T R89L Coil 1b Y Y N F this study
1 G289T K97E Coil 1b Y Y N F (21)
1 A 331G E111X Coil 1b Y Y N F (21)
3 C568T R190W Coil 1b Y Y N F (21)
3 C585G N195K Coil 1b Y Y N F (7)
3 A608G E203G Coil 1b Y Y N F (7)
3 G607A E203K Coil 1b Y Y N F (20)
3 AAG 624-6 K208 Coil 1b Y Y Y Y (8)
4 A665C H222P Coil 1b N Y Y F (35)
4 C673T R225X Coil 1b Y Y N F (20)
4 G746A R249Q Coil 2 Y*/N Y Y S (24)
4 AAG 783-5 K 261 Coil 2 Y Y Y S (35)
5 A881C Q294P Coil 2 Y Y Y S (35)
6 G949A E317K Coil 2 Y Y N F (21)
6 959delT FS R321 Coil 2 Y Y Y F this study†
6 G1072A E358K Coil 2 Y Y Y S (35)
6 T1112A M371K Coil 2 N Y Y S (35)
6 G1130A R377H Coil 2 Y Y Y F this study
6 G1130A R377H Coil 2 ? ? Y F (8)
6 G1157A R386K‡ Coil 2 Y Y Y F (35)
7 C1357T R453W Tail Y Y Y S (24)
7 C1357T R453W Tail Y*/N Y Y S (35)
7 C1357T R453W Tail N Y Y S (24)
8 1397delA FS466 Tail Y N N F (39)
8 T1406C I469T Tail N Y Y F (24)
9 G1580C R527P Tail N Y Y S (24)
9 C1583A T528K Tail N Y Y S (24)
9 G1559C W520S Tail Y Y Y S (35)
9 ctgc 525ins Tail Y Y N F (21)
9 G1580C R527P Tail N Y Y F§ (23)
9 C1583A T528K Tail N Y Y S (35)
Intron 9 G3C Donor splice site Tail Y Y Y F (8)
10 C1711A R571S C-Tail Y Y Y F (7)
11 C1718T S573L A-Tail Y Y N S this study
11 C1930T R644C A-Tail Y N N F (22)
*Identical mutation reported in two unrelated patients (one without cardiomyopathy and one with a mildly dilated cardiomyopathy). †Reported by Brodsky et al. (9). ‡Results
in missense mutation at terminus of exon 6 with predicted disruption of normal exon 6 3 splice site. §Identical mutation reported in two unrelated families. Identical mutation
reported in two unrelated patients.
  termination nonsense; FS  frameshift. Other abbreviations as in Table 2.
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the rod domain, which is conserved among lamins and
cytoplasmic intermediate filaments and is critical for the
higher order assembly of lamin polymers (18). The missense
mutation S573L predicts a change of the highly conserved
sequence and structure of the carboxyl terminal of lamin A,
leaving lamin C intact. This region of the protein controls
the lateral assembly of protofilaments and mediates the
lamin network formation (18).
The majority of gene mutations causing DCM appear to
be private mutations. However, the mutations G1130A,
G746A, and C1357T have been recurrent in apparently
unrelated individuals and may suggest possible hotspots or a
distant founder effect (24). The R377H mutation (G1130A)
found in one of our families has been reported in a LGMD1B
family living in the Caribbean (8). Although a remote founder
effect cannot be excluded, the ethnic backgrounds of the two
families may suggest an independent mutational event. In
keeping with this interpretation is the high rate of occurrence
of LMNA de novo mutations that has been estimated in some
studies to be higher than 50% (35).
The mechanism by which LMNA mutations cause
DCM, conduction disease, and variable degrees of muscular
dystrophy is still not well understood. The missense muta-
tions observed in our population and by other authors
(7,20,21) in a protein known to dimerize and form higher
order assembly structures suggest a dominant negative
mechanism. However, haploinsufficiency appears to be an-
other potential mechanism in a family with EDMD due to
a nonsense mutation in codon 6 (23). Lamin A and C are
believed to have different complex functions: a current
hypothesis is that LMNA mutations result in cellular and
tissue fragility (intermediate filament-fragility syndrome)
(17), particularly in tissues subjected to mechanical stress
(heart and muscle). However, A-lamins have other impor-
tant functions that could cause tissue damage, such as
chromatin organization during cell division, signal trans-
duction, differentiation maintenance, repair, and finally
anchoring of other lamin-binding proteins, such as emerin,
LAP, BAF, and LBR (19). Any of these functions may
potentially lead to cell damage and apoptosis, and eventually
alter myocardial and muscular function.
Genotype-phenotype correlation. Patients with DCM
due to LMNA mutations frequently present with a “mildly”
dilated form with severe dysfunction (38). The presence of
any sign of skeletal muscle abnormality, such as increased
serum creatine kinase, mild signs suggestive of an underly-
ing muscular dystrophy, or family history suggestive of
muscle disease in an affected relative, was a strong predictor
for carrying a LMNA mutation in our study. The presence
of atrioventricular blocks and atrial arrhythmia were also
significantly associated with the carrier status. Contrary to
other autosomal forms of familial DCM (29), we observed
a trend toward an excess of females, perhaps suggesting the
involvement of different “modifier” genes. The exon 11
subject’s sister, who is ostensibly clinically healthy at age 60
years, illustrates an example of a nonpenetrant mutation
carrier which has been reported previously (7,20). The
occurrence of clinically unaffected carriers and the remark-
able inter- and intra-familial variability in the expression of
LMNA mutations (39) suggest the existence of additional
genetic and/or environmental factors contributing to phe-
notype.
Prognosis of LMNA mutations. In our study we found
that subjects with LMNA mutations had a significantly
worse prognosis compared with the other DCM subjects.
Eight of 12 carriers of LMNA mutations were deceased,
required heart transplantation, or had severe worsening of
myocardial function between the third and fifth decade. The
cardiovascular mortality due to sudden death or heart failure
was significantly higher in the carrier group compared with
the DCM patients without LMNA mutations. In each of
the three sets of curves shown in Figure 5, survival was
significantly worse in LMNA mutation carriers compared
with non-carriers with only 31% of event-free survival
(panel C) at age 45 versus 75%.
A relatively milder phenotype with isolated DCM was
observed in the sporadic family where the mutation involves
only the lamin A isoform. Other authors have reported
similar clinical features with mutations restricted to the
lamin C isoform (7). These data suggest that the selective
involvement of lamin C may have a more favorable out-
come.
Study limitations. A potential source of ascertainment bias
in the patient selection was that subjects were recruited in
tertiary care referral centers. Statistical limitations included
the fact that some variables had missing values distributed
sporadically: this pattern precluded multivariate analyses.
Many variables highly correlated with carrier status were
themselves highly correlated: therefore, bivariate results
should not be taken as additive.
Clinical implications. Results of this study provide clinical
insights for genetic counseling and risk stratification of
patients with DCM. Mutations of LMNA are frequent
among patients with DCM, particularly when the disease
is associated with skeletal muscle abnormalities, atrial ar-
rhythmia, or conduction defects. Furthermore, a history
of sporadic DCM does not necessarily exclude a LMNA
gene defect. Taking into account the severity of prognosis
in these patients and the possibility of early interventions
to prevent the progression of heart failure, remodeling, and
sudden death, our findings should prompt screening for
LMNA in familial and sporadic cases of DCM with
clinical indicators suggestive of laminopathy. The avail-
ability of DHPLC with targeted sequence analysis makes
mutation screening efficient and feasible (40). Future studies
should investigate the role of the nuclear envelope in the
pathogenesis of DCM and the existence of modifier
genes, which could alter the expressivity and severity of
the disease, and could represent targets for novel thera-
peutic strategies.
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